ReleaseWire Connect

VADs are of three types — LVADs, BiVADs, and RVADs — that are used to treat heart failure. VADs help the weakened heart to pump blood for circulation to other body organs. Surgeons implant these mechanical devices as a treatment option for severe heart conditions such as acute or chronic cardiac functional deterioration and heart failure.

Cannulae is a flexible tube that is inserted into an artery or vein for different medical purposes such as the administration or removal of fluid from the body intravenously. The condition and medical purpose help determine the cannulas' size ranging from 14 guage to 22 gauge with different color codes. The administration of fluid depends on the size of the gauge: smaller the gauge, larger the diameter and faster the flow of fluid.

Growth Hormone Deficiency-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Growth Hormone Deficiency Report is to understand the market and pipeline status of the drugs around the Growth Hormone Deficiency to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline strategies. The Delve Insight's Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Growth Hormone Deficiency. While the leading brands, companies and chemicals are considered thoroughly, Delve Insight's report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Chronic Asthma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Chronic Asthma Report is to understand the market and pipeline status of the drugs around the Chronic Asthma to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight's Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Chronic Asthma. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight's report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects.

Influenza B Infections - Pipeline Review, H2 2016', provides an overview of the Influenza B Infections pipeline landscape.

Traumatic Brain Injury - Pipeline Review, H2 2016', provides an overview of the Traumatic Brain Injury pipeline landscape.

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2016, provides an overview of the Acute Respiratory Distress Syndrome pipeline landscape.

The Multiple Myeloma Partnering 2010-2015 report provides understanding and access to the multiple myeloma partnering deals and agreements entered into by the worlds leading healthcare companies.

DrugPipeline.net has announced the addition of “Global Mucositis Partnering 2010-2016” research report to their website DrugPipeline.net